NuVasive CEO and leadership

Chris Barry serves as the chief executive officer and a member of the NuVasive Board of Directors.

Prior to this role, Mr. Barry served as senior vice president and president of surgical innovations, the second largest business unit at Medtronic with $5.5 billion in annual revenue, from 2015 to 2018. In this role, Chris provided strategic direction to more than 14,000 employees working in 78 countries, including 10 manufacturing sites and multiple R&D centers. Prior to the acquisition of Covidien by Medtronic, Mr. Barry was president, Advanced Surgical Technologies of Covidien, where he led global strategy, product portfolio and U.S. commercial teams for the $3.2 billion global business unit. Mr. Barry spent more than 15 years in increasing commercial and executive leadership roles at Covidien. Mr. Barry received a bachelor’s degree in environmental science from Texas Tech University.

Mr. Harbaugh brings more than 25 years of experience in finance, business and strategy, and operations management. Most recently, Mr. Harbaugh served as president of the specialty generics business at Mallinckrodt plc. Prior to that, he was Mallinckrodt's CFO for more than five years. During his tenure as CFO, he oversaw the company's accounting, treasury and tax functions, as well as information technology, procurement and facilities. Mr. Harbaugh previously held a variety of financial management positions at Covidien Pharmaceuticals, which was spun-off from Covidien plc as Mallinckrodt plc in July 2013. Mr. Harbaugh joined Covidien in 2007 and served in several finance and leadership roles, including as CFO and interim president of Covidien Pharmaceuticals. Mr. Harbaugh's prior experience includes nearly 10 years at Monsanto Company, where he held various roles in investor relations and finance as well as two ex-patriate positions.

Mr. Harbaugh holds a Bachelor of Science degree in Business Administration from Saint Louis University and an Executive Master of Business Administration degree from Kellogg School of Management at Northwestern University. He was named "Best CFO" in Institutional Investor's 2017 All-America Executive Team.

Chris Barry serves as the chief executive officer and a member of the NuVasive Board of Directors.

Prior to this role, Mr. Barry served as senior vice president and president of surgical innovations, the second largest business unit at Medtronic with $5.5 billion in annual revenue, from 2015 to 2018. In this role, Chris provided strategic direction to more than 14,000 employees working in 78 countries, including 10 manufacturing sites and multiple R&D centers. Prior to the acquisition of Covidien by Medtronic, Mr. Barry was president, Advanced Surgical Technologies of Covidien, where he led global strategy, product portfolio and U.S. commercial teams for the $3.2 billion global business unit. Mr. Barry spent more than 15 years in increasing commercial and executive leadership roles at Covidien. Mr. Barry received a bachelor’s degree in environmental science from Texas Tech University.